Sacubitril/Valsartan Off-Label Uses for Heart Failure

Sacubitril/valsartan (S/V) is an angiotensin receptor-neprilysin inhibitor (ARNI), Food and Drug Administration (FDA) indicated to reduce the risk of cardiovascular (CV) death and hospitalization in patients with left ventricular ejection fraction (LVEF) below normal, with no specified LVEF cut-off.1 The Prospective Comparison of ARNI with angiotensin converting enzyme inhibitors (ACE-I) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial showed sacubitril/valsartan's superiority over enalapril in patients with chronic heart failure (HF) with reduced EF.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research